PMV Pharma Narrows Q2 Loss, Plans Rezatapopt NDA in Q1 2027
PMVP sits 19% above its 52-week low of $1.02 on light trading volume (0.3× avg).
Summary
PMV Pharmaceuticals reported a narrower Q2 net loss of $18.09 million ($0.34 per share) driven by lower R&D and G&A costs. The company completed enrollment in the Phase 2 PYNNACLE trial for rezatapopt in platinum-resistant ovarian cancer and plans an NDA submission in Q1 2027. Cash runway is expected through Q2 2027, addressing the going concern warning from the 10-Q filed today. The stock trades at $1.22 with a median analyst price target of $4.00, reflecting significant upside if the NDA progresses.
At the time of this announcement, PMVP was trading at $1.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $64.8M. The 52-week trading range was $1.02 to $1.88. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.